Xencor, Vir partner on COVID-19 antibodies research

By The Science Advisory Board staff writers

March 27, 2020 -- Biopharmaceutical companies Xencor and Vir Biotechnology have entered into a technology licensing agreement to develop potential antibody-based treatments for patients with COVID-19.

Under the agreement, Vir will receive nonexclusive access to Xencor's Xtend Fc technology that extends the half-life of antibodies. Vir will also be responsible for costs and activities pertaining to research, development, regulatory, and commercial actions.

The two companies previously partnered in 2019 on developing and commercializing antibodies for influenza and hepatitis B infections.

If you like this content, please share it with a colleague!

Related Reading

Controversy hits Gilead over orphan status for COVID-19 drug
Gilead Sciences has rescinded its request for orphan drug status for an experimental drug for treating COVID-19 just two days after getting approval from...

COVID-19 causes long-term disruptions to clinical trials
New survey results suggest that clinical trials are experiencing significant roadblocks associated with COVID-19. These could ultimately result in a slowdown...

Dynavax, Clover partner for protein-based COVID-19 vaccine
A new research collaboration between Dynavax Technologies and Clover Biopharmaceuticals aims to develop a vaccine candidate to prevent COVID-19. The partnership,...

Frontera supercomputer aids COVID-19 drug development
Scientists are urgently working to build the first complete all-atom model of the SARS-CoV-2 coronavirus envelope, estimated to contain over 200 million...

TriNetX updates platform to support COVID-19 research
Global health research network TriNetX said that it has updated its real-world data platform to incorporate specific terminology for COVID-19 test results.